ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "lymphocytes"

  • Abstract Number: 154 • 2020 Pediatric Rheumatology Symposium

    T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis

    Anna Patrick1, Tashawna Esmond 2, David Flaherty 2, Thomas Brent Graham 2, Susan Thompson 3 and Thomas Aune 1, 1Vanderbilt University Medical Center, Nashville, Tennessee, 2Vanderbilt University Medical Center, Nashville, 3Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common autoimmune arthritis in children.  Polyarticular JIA and extended oligoarticular JIA both have genetic associations near genes…
  • Abstract Number: 610 • 2019 ACR/ARP Annual Meeting

    Ankylosing Spondylitis-associated Killer Immunoglobin-like Receptors Are Strongly Expressed on γδ T Cells

    Micah Lefton1, Nihaarika Sharma 1 and Joerg Ermann 2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston

    Background/Purpose: The mechanism underlying the association between ankylosing spondylitis (AS) and HLA-B27 is still unknown. One of the hypotheses involves the interaction of HLA-B27 homodimers…
  • Abstract Number: 2519 • 2019 ACR/ARP Annual Meeting

    Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE

    Daniel Strasser 1, Virginie Sippel 1, Ursula Grieder 1, Andrea Kieninger-Graefitsch 2, Gabin Pierlot 1, Hervé Farine 1, Paulina Kulig 1, Geoffroy Bourquin 1, Marcel Keller 1, Peter Groenen 1, Marten Trendelenburg 2 and Mark Murphy1, 1Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, 2University Hospital Basel, Basel, Switzerland

    Background/Purpose: SLE is an autoimmune disease driven by autoreactive T and B lymphocytes. Lymphocytes infiltrate self-antigen expressing tissues, in which tertiary lymphoid structures are often…
  • Abstract Number: 2570 • 2019 ACR/ARP Annual Meeting

    Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis

    Amira El Gerby 1, Abeer Abdelati 2, Hanaa Donia 3 and Nouran Eshak4, 1Rheumatology Department, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt, 2alexandria university, alexandria, Egypt, 3Clnical and Chemical Pathology Department, Faculty of Medicine, ALexandria University, Alexandria, Egypt, 4Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Lubbock, TX

    Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search…
  • Abstract Number: 1110 • 2018 ACR/ARHP Annual Meeting

    Characterization of CD20+ T Cells in Patients with Systemic Sclerosis

    Monica D'Orazio1, Elisabeth Fliesser2, Florentine Moazedi-Fürst3, Martin Stradner4, Sonja Kielhauser3, Johannes Fessler5 and Hans-Peter Brezinschek1, 1Internal Medicine/Division of Rheumatoloy and Immunology, Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, 2Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 3Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, 4Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 5Department of Neurology, Harvard Medical School, Boston, MA

    Background/Purpose: Recently, it has been demonstrated that a subset of T cells expresses the B-cell marker CD20. It has been postulated that in rheumatoid arthritis…
  • Abstract Number: 2038 • 2018 ACR/ARHP Annual Meeting

    Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis

    Satoshi Kubo1, Shingo Nakayamada1, Yusuke Miyazaki1, Maiko Yoshikawa2, Hiroko Yoshinari3, Shigeru Iwata4, Kentaro Hanami2, Shunsuke Fukuyo3, Ippei Miyagawa5, Kazuhisa Nakano1 and Yoshiya Tanaka6, 1First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3University of Occupational and Environmental Health, Japan, Fukuoka, Japan, 4First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6University of Occupational and Environmental Health, Kitakyushu, Japan

    Background/Purpose: In the treatment of rheumatoid arthritis (RA), molecular targeted therapies induced different changes in different immune cell phenotypes. For instance, our previous study showed…
  • Abstract Number: 2586 • 2018 ACR/ARHP Annual Meeting

    Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis

    Gerd R. Burmester1, William FC Rigby2, Ernest Choy3, Peter Nash4, Kevin Winthrop5, Philip J. Mease6, Pamela Young7, Thijs Hendrikx7, Cunshan Wang8, Sujatha Menon8 and Daniela Graham8, 1Charité – University Medicine Berlin, Berlin, Germany, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Cardiff University School of Medicine, Cardiff, United Kingdom, 4University of Queensland, Brisbane, Australia, 5Oregon Health and Science University, Portland, OR, 6Swedish Medical Center and University of Washington, Seattle, WA, 7Pfizer Inc, Collegeville, PA, 8Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of psoriatic arthritis (PsA). Cytokines involved in lymphocyte development, function, and homeostasis signal…
  • Abstract Number: 685 • 2018 ACR/ARHP Annual Meeting

    Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

    William FC Rigby1, Gerd R. Burmester2, Oliver FitzGerald3, Valderilio F Azevedo4, Peter Nash5, Thijs Hendrikx6, Daniela Graham7, Cunshan Wang7 and Thomas Jones6, 1Geisel School of Medicine at Dartmouth, Lebanon, NH, 2Charité – University Medicine Berlin, Berlin, Germany, 3Department of Rheumatology, St Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College, Dublin, Ireland, 4Universidade Federal do Paraná, Curitiba, Brazil, 5University of Queensland, Brisbane, Australia, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is…
  • Abstract Number: 660 • 2017 ACR/ARHP Annual Meeting

    Strain-Dependent IL-17A Secretion By CD4-CD8- DN αβ T Cells Correlates with Disease Susceptibility in Murine Spondyloarthritis

    Imtiyaz Hossain, Mederbek Matmusaev and Joerg Ermann, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Hydrodynamic injection of IL-23 minicircles into adult B10.RIII mice induces an inflammatory disease with phenotypic features of human spondyloarthritis. Tissue-resident CD4-CD8- double negative (DN)…
  • Abstract Number: 961 • 2017 ACR/ARHP Annual Meeting

    Adalimumab Reduces CXCR4 Expression during Inflammatory Arthritis and in Fibroblast-like Synoviocytes and Osteoclasts Under Chronic TNF Exposure

    Bohdan P. Harvey1, Li Li1, Mark Konrad1, Heather Knight1, Susan Westmoreland2, Melanie Ruzek1 and Zehra Kaymakcalan1, 1AbbVie Bioresearch Center, Worcester, MA, 2AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: The CXCL12/CXCR4 chemokine axis has been implicated in the pathogenesis of RA. The expression of this chemokine and receptor has been shown to be…
  • Abstract Number: 1427 • 2017 ACR/ARHP Annual Meeting

    Monitoring of Absolute Lymphocyte Count in Patients with Rheumatoid Arthritis Treated with Tofacitinib

    Gerd R. Burmester1, Zoltan Szekanecz2, Pinaki Biswas3, Sriram Krishnaswami4, Christopher F Mojcik3, Hernan Valdez3, Jamie Geier3 and Sander Strengholt5, 1Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 2University of Debrecen Faculty of Medicine, Debrecen, Hungary, 3Pfizer Inc, New York, NY, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Capelle aan den IJssel, Netherlands

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Lymphopenia is a frequent feature of RA,1 and RA medications may also…
  • Abstract Number: 2125 • 2017 ACR/ARHP Annual Meeting

    Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study

    Okinori Murata1, Atsuko Kudo2 and Katsuya Suzuki3, 1Department of Pulmonary medicine, Hachinohe Red Cross Hospital, Hachinohe, Japan, 2Hachinohe Red Cross Hospital, Hachinohe, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan

    Background/Purpose: Sarcoidosis is a systemic granulomatous disease that can affect multiple organs, and in particular lung involvements are common and found in more than 90%…
  • Abstract Number: 2596 • 2017 ACR/ARHP Annual Meeting

    Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients

    Samantha Slight-Webb1, Rufei Lu2, Hua Chen1, Holden T. Maecker3, Paul J. Utz4, Joel M. Guthridge5 and Judith A. James6, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 4Medicine, Stanford University School of Medicine, Stanford, CA, 5Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has been used for decades to treat various rheumatic diseases including systemic lupus erythematosus (SLE). The efficacy of HCQ…
  • Abstract Number: 286 • 2016 ACR/ARHP Annual Meeting

    Clinical Significance and Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients with Dermatomyositis

    Jaehyung Hur1, Dong Jin Go2, Sang Wan Chung3, You Jung Ha3, Eun Ha Kang1, Jin Kyun Park4, Eun Young Lee2, Eun Bong Lee2, Yeong Wook Song4 and Yun Jong Lee5, 1Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, 3Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea

    Background/Purpose:  Recent studies have suggested that neutrophil to lymphocyte ratio (NLR) could be an emerging predictive marker of disease activity or mortality in patients with…
  • Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting

    Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis

    Paul-Peter Tak1,2,3, Marieke E. Doorenspleet4, Maria de Hair5, Paul L. Klarenbeek6, Marian van Beers-Tas7, Antoine H.C. van Kampen8, Dirkjan van Schaardenburg9,10, Danielle M. Gerlag11,12, Frank Baas13 and Niek de Vries14, 1Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Currently: GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 3currently: Ghent University, Ghent, Belgium & Cambridge University, Cambridge, United Kingdom, 4Dept. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 5Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 6Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 7Rheumatology, Amsterdam Rheumatology & Immunology Center, Reade, Amsterdam, Netherlands, 8Dept Clin Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, 9Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 10Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, 11Clinical Immunology & Rheumatology, ARC | Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 12Current address: GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom, 13Department of Genome Analysis, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, 14Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.